[Value of transtracheobronchial ultrasonography in the assessment of mediastinal lymphadenopathy in patients with lung cancer].
Motoyasu Sagawa(Tohoku University), S Fujimura, Hisashi Takahashi, Morio Sato, Muneo Minowa, Kiyotoshi Inoue, Shunichi Sugawara(Sendai Kousei Hospital), C Endo, Hiroyoshi Tsubochi, Akira Sakurada(Tohoku University Hospital)
PubMed
June 1, 1998
Cited by 4
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695